Biologics

Tissue Regenix Announces Proposed Acquisition of CellRight Technologies

July 21, 2017

SAN ANTONIO–(BUSINESS WIRE)–Tissue Regenix, the UK-based regenerative medical devices company, today announced the proposed acquisition of CellRight Technologies, a U.S. regenerative medicine company based in San Antonio, TX. This acquisition would bring together two highly complementary technology and product platforms focused on soft-tissue regeneration and regenerative bone matrices, respectively.

The deal accelerates both companies’ vision to becoming a global leader in regenerative medicine by accelerating growth and penetration into key U.S. markets. The combined group will have a highly complementary product offering with CellRight Technologies’ existing orthopedic portfolio, based on human-derived bone graft products, and Tissue Regenix’s soft tissue products based on its patented decellularisation dCELL® Technology (dCELL®), a multi-tissue regenerative medical platform.

The combined group provides CellRight Technologies with the infrastructure of a larger, multi-national organization and a platform to enter new geographies. CellRight Technologies’ human tissue-based products, including Matrix OI, will expand the current Tissue Regenix portfolio, which includes DermaPure® for wound care applications. Additionally, CellRight Technologies’ existing tissue bank in San Antonio, TX, provides Tissue Regenix with a purpose built U.S. base to self-manufacture products utilizing its patented dCELL® process.

Combined with the capabilities of CellRight Technologies’ osteobiologics, this acquisition positions Tissue Regenix to launch into the U.S. orthopedics market in early 2018 with a focus on ligament reconstruction, initially addressing anterior cruciate ligament repair, through OrthoPure® HT, a decellularised human tendon.

“We are excited by the huge potential that this acquisition brings for the advancement of regenerative medicine to our patients globally,” said Antony Odell, CEO of Tissue Regenix. “We are combining two highly complementary companies that are committed to developing a robust portfolio of products and we are poised for rapid growth through our existing product offering with plans for multiple U.S. launches over the next two years.”

CellRight Technologies has seen tremendous success in the U.S., including leveraging strong relationships with orthopedics and sports medicine companies. Founder and CEO Jesus Hernandez has been at the heart of research and development for the CellRight Technologies product line.

“Becoming part of the Tissue Regenix family is an exciting and important milestone for our company,” said Jesus Hernandez, founder and CEO of CellRight Technologies. “With the combined talent and expertise in biologics, we look forward to continuing to lead regenerative medicine, bringing our patients and healthcare partners the products and innovation which enhance their lives. We are all excited at the potential of what we will be able to accomplish together.”

For more information about Tissue Regenix, please visit http://www.tissueregenix.com/.

Important notice

The information contained herein is not for release, directly or indirectly, in or into Australia, Canada, Japan or the Republic of South Africa. This document (and the information contained herein) does not contain or constitute an offer of securities for sale, or solicitation of an offer to purchase securities, in the United States, Australia, Canada, Japan or the Republic of South Africa or any other jurisdiction where such an offer or solicitation would be unlawful. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States unless the securities are registered under the Securities Act, or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. No public offering of the securities will be made in the United States.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company’s patented decellularisation (‘dCELL®’) Technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient’s body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

About CellRight Technologies

CellRight Technologies is the industry leader of osteoinductive matrices and is committed to providing clinicians and their patients with verified osteoinductive implants known to positively impact patient and fusion outcomes. In-vivo and in-vitro testing to verify osteoinductivity is performed post-sterilization by an independent testing laboratory using validated osteoinductivity test methods.

Contacts

Racepoint Global
Jeff Stoecker, +1-617-624-3424
jstoecker@racepointglobal.com

Print Friendly, PDF & Email
Tags

Drue De Angelis

Drue is Managing Partner for The De Angelis Group, Executive Search firm exclusively for the Ortho & Spine industry.

Related Articles

Back to top button
Close